1:45
Immunotherapy Success in KRAS G12C Adenosquamous Pancreatic Cancer | Oncotarget
Oncotarget
1:46
Targeting ABC Transporters in PDAC – Past, Present or Future? | Oncotarget
2:12
Synergistic Effects of HDAC, PARP Inhibitors, and Decitabine in Pancreatic Cancer | Oncotarget
1:20
Pancreatic Adenocarcinoma: Genetic Insights & Machine Learning Analysis | Oncotarget
1:47
Immune Responses in Pancreatic Cancer: Primary vs. Metastatic | Oncotarget
8:49
HER3: A Vital Target in Cancer Treatment | Oncotarget
2:27
Real Time Ex Vivo Chemosensitivity Assay for Pancreatic Adenocarcinoma | Oncotarget
1:52
HER3: Survival Pathway and Therapeutic Target in Colorectal and Pancreatic Cancer | Oncotarget
1:00
Oncotarget | Effects of Metformin and Rapamycin in Pancreatic Cancer
0:59
Oncotarget: Alternative RNA Splicing in Pancreatic Cancer
0:51
Oncotarget: C. Elegans Sniff Out Early Pancreatic Cancer
0:44
Oncotarget: Mebendazole Used to Treat Pancreatic Cancer
0:53
Oncotarget: Dynamic Changes Throughout Pancreatic Cancer Treatment
2:31
Oncotarget: Cis-acting elements in 3′ UTR mediate post-transcriptional regulation of KRAS
11:36
Oncotarget: Significant differences in biomarker expression in pancreatic cancer
6:52
Oncotarget: Targeting mesothelin with high cytotoxic activity
10:51
Oncotarget: Phenanthrene exclusively eradicates human pancreatic cancer cells in xenografts
